Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study

CONCLUSION: Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.PMID:38427969 | DOI:10.1093/ajhp/zxae053

Source: American Journal of Health-System Pharmacy : AJHP - March 1, 2024 Category: Drugs & Pharmacology Authors: Munaza Riaz Steven M Smith Eric A Dietrich David E Winchester Jingchuan Guo Haesuk Park Source Type: research